These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6575727)

  • 1. [Adriamycin-aclacinomycin therapy (AA therapy) for acute leukemia unresponsive to BH-AC-DMP therapy].
    Kobayashi M; Tahara T
    Gan To Kagaku Ryoho; 1983 Jun; 10(6):1473-9. PubMed ID: 6575727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of acute non-lymphocytic leukemia with concurrent administration of N4-behenoyl-beta-D-arabinofuranosylcytosine, aclacinomycin A, 6-mercaptopurine and prednisolone; a pilot study (author's transl)].
    Hirano M; Morishita Y; Ino T; Matsui T; Shimizu S; Shigemura H; Nakamura K; Ono Y; Saito M
    Rinsho Ketsueki; 1981 Mar; 22(3):299-305. PubMed ID: 6944508
    [No Abstract]   [Full Text] [Related]  

  • 3. [Combination chemotherapy of N(4)-behenoyl-1-beta-arabinofuranosylcytosine, aclarubicin, 6-MP, and prednisolone (BH-AC. AMP therapy) for adult acute non-lymphocytic leukemia].
    Ishige K; Takagi T; Oguro M
    Gan To Kagaku Ryoho; 1984 Jul; 11(7):1475-9. PubMed ID: 6588925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mucosal injury of aclacinomycin A in patients with adult acute leukemia--comparison of BH-AC. AMP therapy and BH-AC. DMP therapy].
    Takeyama H; Kataoka T; Yano K; Fukutani H; Watanabe E
    Rinsho Ketsueki; 1986 Apr; 27(4):508-13. PubMed ID: 3461186
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparative evaluation of combined chemotherapeutic regimens in acute non-lymphocytic leukemia].
    Sasaki H; Maekawa I; Kawamura S; Miyake T
    Hokkaido Igaku Zasshi; 1983 May; 58(3):271-8. PubMed ID: 6194091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of acute myelogenous leukemia with concurrent administration of N4-behenoyl-ara-C, aclacinomycin A, 6-mercaptopurine and prednisolone].
    Ino T; Saito M; Matsui T; Shimizu S; Shigemura H; Nakamura K; Ono Y; Okamoto M; Takada T; Imura H
    Rinsho Ketsueki; 1985 Feb; 26(2):139-46. PubMed ID: 3860668
    [No Abstract]   [Full Text] [Related]  

  • 7. Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia.
    Nagura E; Kimura K; Yamada K; Ohta K; Maekawa T; Takaku F; Uchino H; Masaoka T; Amaki I; Kawashima K
    Cancer Chemother Pharmacol; 1994; 34(1):23-9. PubMed ID: 8174198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gastrointestinal symptoms of aclacinomycin A in patients with adult acute nonlymphocytic leukemia--comparison of BH-AC-DMP therapy and BH-AC-AMP therapy].
    Kawano F; Tajima H; Matsuoka Y; Asou N; Takatsuki K
    Rinsho Ketsueki; 1985 Apr; 26(4):494-8. PubMed ID: 3862889
    [No Abstract]   [Full Text] [Related]  

  • 9. [A case of acute promyelocytic leukemia complicated with severe esophageal stenosis caused by aclacinomycin A].
    Kataoka T; Takeyama H; Watanabe E; Yano K
    Gan To Kagaku Ryoho; 1985 Aug; 12(8):1686-9. PubMed ID: 3861136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [ABEP chemotherapy in the treatment of advanced non-Hodgkin's lymphomas].
    Yoshida T; Nakanishi J; Ito K; Kobayashi K; Ohtake S; Nakamura S; Matsuda T; Nakagoshi T; Natori K; Nakamura E
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):984-9. PubMed ID: 3963862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behenoyl cytosine arabinoside, aclacinomycin A, 6-mercaptopurine, and prednisolone combination therapy for acute non-lymphocytic leukaemia in adults.
    Yoshida M; Suda K; Tsuboyama A; Sasaki R; Kitagawa S; Kano Y; Muto Y; Takaku F; Sakamoto S; Miura Y
    Eur J Haematol; 1989 Jul; 43(1):1-6. PubMed ID: 2767238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aclacinomycin A and behenoyl arabinofuranosylcytosine combination chemotherapy for previously untreated acute leukemia.
    Sampi K; Sakurai M; Kaneko Y; Hattori M
    Oncology; 1986; 43(1):18-22. PubMed ID: 3455751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Aclacinomycin A and behenoyl ara-C combination chemotherapy for untreated acute non-lymphocytic leukemia].
    Sampi K; Honda T; Hayashi Y; Hattori M
    Gan To Kagaku Ryoho; 1983 Oct; 10(10):2211-6. PubMed ID: 6578705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [BH-AC.AMP protocol in the treatment of refractory childhood acute leukemia].
    Nakadate H; Hatayama Y; Hatae Y; Takeda T
    Gan To Kagaku Ryoho; 1988 Oct; 15(10):2907-10. PubMed ID: 3178240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Remission induction by ACM-A and BH-AC on acute promyelocytic leukemia which is resistant to DNR and CA (author's transl)].
    Shimazaki C; Nakajima Y; Ura Y; Hamami T; Haruyama H; Isemura T; Nakagawa M; Ijichi H
    Rinsho Ketsueki; 1981 Jul; 22(7):1116-22. PubMed ID: 6948970
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of acute non-lymphocytic leukemia with alternating non-cross resistant chemotherapy.
    Kyo T; Dohy H
    Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1641-52. PubMed ID: 3247827
    [No Abstract]   [Full Text] [Related]  

  • 17. [Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
    Takahashi I; Hara M; Ohmoto E; Oda Y; Endo Y; Fujimoto S; Uchida K; Takaoka K; Watanabe S; Lai M; Kohi F; Kitajima K; Kimura I; Sanada H; Tokioka M; Adachi T; Yorimitsu S
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1617-22. PubMed ID: 6964050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic results with aclacinomycin A in recurring acute leukemias].
    Mitrou PS
    Onkologie; 1983 Aug; 6(4):192-4. PubMed ID: 6355949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
    Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
    Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of conventional chemotherapy and short-term intensive chemotherapy in adult acute myeloid leukemia].
    Ohshima T
    Rinsho Ketsueki; 1989 Aug; 30(8):1175-7. PubMed ID: 2601028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.